Seattle Genetics Inc (SGEN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The companys lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) indicated for the treatment of relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics product pipeline consists of ASG-22ME (enfortumab vedotin) for metastatic urothelial cancer. Its pipeline also comprises various antibody-drug conjugate (ADC) programs and immuno-oncology programs in various clinical stages of development. It uses ADC and sugar-engineered antibody (SEA) technologies for the development of its product portfolio. The company sells its products through pharmaceutical distributors and collaborators. Seattle Genetics is headquartered in Bothell, Washington, the US.

Seattle Genetics Inc (SGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Seattle Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 13
Venture Financing 14
Unum Therapeutics Raises USD65 Million in Series B Financing 14
Partnerships 16
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 16
Seattle Genetics Enters into Agreement with Genentech 17
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 18
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 19
Genmab Enters into Research Agreement with Seattle Genetics 20
Seattle Genetics Expands Co-Development Agreement With AbbVie 22
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 23
Licensing Agreements 24
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 24
Seattle Genetics Enters into Licensing Agreement with Pieris Pharma 25
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 26
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 27
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 28
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 29
Equity Offering 30
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 30
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 31
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 33
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 35
Acquisition 36
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 36
Seattle Genetics Acquires 2.8% Stake in Immunomedics 38
Seattle Genetics Inc - Key Competitors 40
Seattle Genetics Inc - Key Employees 41
Seattle Genetics Inc - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Apr 26, 2018: Seattle Genetics Reports First Quarter 2018 Financial Results 43
Feb 06, 2018: Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results 45
Oct 26, 2017: Seattle Genetics Reports Third Quarter 2017 Financial Results 48
Jul 27, 2017: Seattle Genetics Reports Second Quarter 2017 Financial Results 50
Apr 27, 2017: Seattle Genetics Reports First Quarter 2017 Financial Results 52
Feb 09, 2017: Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results 54
Corporate Communications 56
May 17, 2018: Seattle Genetics Appoints Roger D Dansey M D Chief Medical Office 56
Product News 57
04/03/2017: Unum Therapeutics to Present New Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming American Association for Cancer Research 2017 Annual Meeting 57
Mar 30, 2017: Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting 59
01/21/2017: Johnson & Weaver Announces Filing of Class Action Complaint Against Seattle Genetics Encourages all Investors to Contact the Firm for Information 61
Jan 08, 2018: Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference 62
01/04/2018: Cascadian Therapeutics Announces 2018 Outlook and Recent Progress 63
01/04/2017: Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and Quality 65
Product Approvals 66
Jan 02, 2018: Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency 66
Sep 27, 2017: Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer 67
Jul 11, 2017: Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe 68
Jun 08, 2017: Cascadian Therapeutics Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases 69
Clinical Trials 70
Dec 07, 2017: Prolonged Progression-Free Survival Reinforces Tucatinibs Potential for Patients with Advanced HER2+ Metastatic Breast Cancer 70
Dec 07, 2017: Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium 72
Sep 11, 2017: Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology 2017 Congress 74
Aug 28, 2017: Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology 2017 Congress 76
Apr 05, 2017: Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017 77
Mar 06, 2017: FDA Lifts Clinical Hold on Seattle Genetics Phase 1 Trials of Vadastuximab Talirine 78
Jan 10, 2017: Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer 79
Jan 05, 2017: Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List Of Tables

List of Tables
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seattle Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Seattle Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 13
Unum Therapeutics Raises USD65 Million in Series B Financing 14
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 16
Seattle Genetics Enters into Agreement with Genentech 17
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 18
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 19
Genmab Enters into Research Agreement with Seattle Genetics 20
Seattle Genetics Expands Co-Development Agreement With AbbVie 22
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 23
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 24
Seattle Genetics Enters into Licensing Agreement with Pieris Pharma 25
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 26
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 27
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 28
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 29
Unum Therapeutics Raises USD5 Million in Private Placement of Shares 30
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 31
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 33
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 35
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 36
Seattle Genetics Acquires 2.8% Stake in Immunomedics 38
Seattle Genetics Inc, Key Competitors 40
Seattle Genetics Inc, Key Employees 41
Seattle Genetics Inc, Subsidiaries 42

List Of Figures

List of Figures
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Seattle Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

2018 Biotechnology Competitive Intelligence: Seattle Genetics Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series, which includes current assessments of more than 1,000 companies worldwide. The assessments include all or some of the following: Organization and

USD 950 View Report

Seattle Genetics: Performance, Capabilities, Goals and Strategies in the Global Biotechnology Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

2018 Biotechnology Competitive Intelligence: Seattle Genetics Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series, which includes current assessments of more than 1,000 companies worldwide. The assessments include all or some of the following: Organization and

USD 950 View Report

Veritas Genetics Inc - Medical Equipment - Deals and Alliances Profile

Veritas Genetics Inc (Veritas Genetics) is a genome sequencing company that offers genomics testing and sequencing products and services. The company delivers actionable genetic insights to individuals and their doctors

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available